ALT 803

Drug Profile

ALT 803

Alternative Names: ALT803; IL-15N72D:IL-15RαSu/Fc fusion protein complex

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Altor BioScience Corporation; NantKwest
  • Developer Altor BioScience Corporation; Masonic Cancer Center; NantCell; NantKwest; National Cancer Institute (USA); University of Minnesota; University of South Carolina
  • Class Antibacterials; Antineoplastics; Antivirals; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin-15 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Bladder cancer
  • Phase II Acute myeloid leukaemia; Merkel cell carcinoma; Non-small cell lung cancer
  • Phase I/II Breast cancer; Colorectal cancer; Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma; Pancreatic cancer; Solid tumours; Squamous cell cancer
  • Phase I Fallopian tube cancer; HIV infections; Malignant melanoma; Ovarian cancer; Peritoneal cancer
  • Preclinical Bacterial infections

Most Recent Events

  • 29 Jun 2018 NantKwest initiates enrolment in the QUILT 3.071 phase I/II trial for Colorectal cancer (Combination therapy, Metastatic disease, late-stage disease, Second-line therapy or greater) in USA (NCT03563157)
  • 20 Jun 2018 NantKwest plans the QUILT-3.088 phase II trial for Pancreatic Cancer (Metastatic disease) in USA , (NCT03563144)
  • 20 Jun 2018 NantKwest plans a phase II QUILT-3.057 trial for Triple negative breast cancer (First-line therapy, Combination therapy, Neoadjuvant therapy) in USA (NCT03554109)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top